
    
      To evaluate the safety and efficacy of multimodality treatment of pre- and post-operative
      durvalumab therapy after pre-operative chemoradiotherapy for resectable superior sulcus tumor
      (SST) and durvalumab maintenance therapy after chemoradiotherapy for unresectable SST
    
  